/C O R R E C T I O N from Source -- Biosign Technologies Inc./

In c4239 transmitted on Monday, September 19, 2011 by Cloud Dx, the company designation as Cloud Dx was incorrect. Corrected copy follows:

Biosign Response to Annual Shareholder Meeting Questions

SAN FRANCISCO, Sept. 19, 2011 /CNW/ - Biosign Technologies Inc. (TSXV: BIO), a medical device company focused on non-invasive, cloud-based vital health monitoring, held its annual shareholders meeting last week. All matters of business as described in the Information Circular were approved, including the election of Steven Bloom to the Board of Directors and the ratification of the company's employee stock option plan.

Dr. Scott Jenkins, CEO of the company, reviewed with shareholders the patient and disease management market globally and provided an overview of the competitive landscape. Dr. Jenkins also announced Cloud Dx, a division of Biosign, is launching a business model for reducing the cost of healthcare utilization by providing an active cloud-based vital health monitoring system that allows providers to deliver the best quality of care to patients. A copy of Dr. Jenkins' presentation can be found at: http://www.biosign.com/news.htm.

Steven Bloom was elected to the Board of Directors and subsequently appointed by the board as the Chair of the Audit Committee. Mr. Bloom is the Senior Vice President, Finance at Kilmer Van Nostrand Co. Limited. He has served in various financial leadership positions, including Partner and Chief Financial Officer, Brightspark Capital; Chief Financial Officer, Think Dynamics; Vice President, Finance, Descartes Systems Group; and Manager, Ernst and Young.

Mr. Bloom is a Chartered Accountant and holds an Honors of Business Administration degree from the University of Western Ontario-Richard Ivey School of Business.

"We are very fortunate to have Steven Bloom on our board," says Dr. Jenkins, CEO. "Steven's extensive and diverse financial experience will benefit our Audit Committee and bring a fresh perspective to the board."

In addition to the approval of the employee stock option plan, 300,000 stock options were granted to a director on September 12, 2011, pursuant to the company's stock option plan at an exercise price of $ 0.74 per share.

About Biosign Technologies Inc

Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Cloud Dx applications include intelligent systems for non-invasive monitoring of common health risks associated with blood pressure, glucose, and medication. Biosign technology combines measurement, analysis, and tools for disease and patient management to support global vital health monitoring. The UFIT® medical device delivers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation and management, and remote patient monitoring. For more information visit: www.biosign.com.

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Biosign Technologies Inc.

For further information:

Biosign/Cloud Dx Contact:

Investor Relations
Jeff Miller
(650) 281-5376

Public Relations
JP Isham
(415) 967-0490

Profil de l'entreprise

Biosign Technologies Inc.

Renseignements sur cet organisme


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.